Brief: Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt Drop
16/12/2025 13:37
Dec 16 (Reuters) - Nektar Therapeutics NKTR.O: NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY ACHIEVED TARGET PRODUCT PROFILE WITH 28.2% SALT SCORE REDUCTION NEKTAR THERAPEUTICS - REZPEGALDESLEUKIN WELL TOLERATED WITH CONSISTENT SAFETY PROFILE NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY RESULTS SUPPORTS ADVANCEMENT TO PHASE 3 DEVELOPMENT IN ALOPECIA AREATA NEKTAR THERAPEUTICS - BOTH REZPEGALDESLEUKIN TREATMENT ARMS MET STATISTICAL SIGNIFICANCE EXCLUDING VIOLATIONS Source text: ID:nPn2425Kpa Further company coverage: NKTR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nektar Therapeutics
See all newsBrief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says